Clinical Trial Update: Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH) [Phase 3]

View source ↗

Summary

Phase 3 trial results report on the efficacy and safety of Telmisartan (Micardis) or hydrochlorothiazide in patients with isolated systolic hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Isolated Systolic Hypertension

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
• Micardis (telmisartan)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hypertension | Phase 3 | Status: COMPLETED